Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Recruiting 6Active not recruiting 4Not yet recruiting 3Completed 3Withdrawn 1Suspended 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Leukemia, Myeloid, Acute 7Carcinoma, Renal Cell 3Triple Negative Breast Neoplasms 2Myelodysplastic Syndromes 2Multiple Myeloma 2Lymphoma, T-Cell 2Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Colorectal Neoplasms 2Clear-cell metastatic renal cell carcinoma 2Breast Neoplasms 2Waldenstrom Macroglobulinemia 1Thrombocytosis 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Synovial 1Sarcoma, Clear Cell 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Rhabdomyosarcoma 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neurofibrosarcoma 1Neuroblastoma 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Mouth Neoplasms 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell, Marginal Zone 1

Interventions

Specimen Handling 8Nivolumab 6pembrolizumab 4lenvatinib 3Ipilimumab 3Biopsy 3Axitinib 3vorolanib 2fludarabine 2cabozantinib 2anlotinib 2Sunitinib 2Nephrectomy 2Magnetic Resonance Spectroscopy 2Cyclophosphamide 2CTLA-4 Antigen 2toripalimab 1tivozanib 1sodium-iodide symporter 1sintilimab 1pazopanib 1fludarabine phosphate 1cemiplimab 1bemarituzumab 1belzutifan 1balstilimab 1Zoledronic Acid 1Saline Solution 1Rubidium-82 1Radiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Not yet recruiting × Carcinoma, Renal Cell × Biopsy × Clear all
NCT07510334 2026-04-03

VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Mayo Clinic

Phase 2 Not yet recruiting
18 enrolled
Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT07226544 2025-11-10

Ivonescimab Prior to Surgery for the Treatment of High-Risk Localized Clear Cell Renal Cell Cancer

City of Hope Medical Center

Phase 2 Not yet recruiting
31 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT07218692 2025-10-20

RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy

City of Hope Medical Center

Phase 2 Not yet recruiting
35 enrolled
Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡